ProMIS’s PMN310 Antibody Therapy Binds Only to Toxic Forms of Amyloid Beta, Study Reports

ProMIS’s PMN310 Antibody Therapy Binds Only to Toxic Forms of Amyloid Beta, Study Reports
An antibody therapy that ProMIS Neurosciences is developing for Alzheimer's formed a bond with only the harmful forms of amyloid beta clusters associated with the disease, an indication that it could be an effective treatment, according to a preclinical-trial study. A good sign was that PMN310 didn't bind to the forms that are non-toxic, ProMIS said. The study compared PMN310's binding characteristics with that of other amyloid beta-directed antibodies for Alzheimer’s. An antibody is a protein that the immune system produces when it detects harmful substances. An antibody therapy involves using an antibody to manage a condition. “We are pleased to confir
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *